Laropiprant
As of the edition of 20 October 2026, Laropiprant is a small molecule: withdrawn from the market in 2013; acts on PTGDR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2013
- Kind
- Small molecule
- Withdrawn from market
- 10 April 2013 (in some regions)
- Registered trials
- 27, 8 stopped early
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Hormones; Heart and blood vessels; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGDR | Prostaglandin D2 receptor | Q13258 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 12 | 8 | 0 | 4 |
| Phase 4 | 5 | 3 | 0 | 2 |
| All trials | 27 |